Summary of evan hughes's the hard sell
(2022)
By: IRB Media

Nonfiction

eBook

Provider: hoopla

Details

PUBLISHED
[United States] : IRB, 2022
Made available through hoopla
DESCRIPTION

1 online resource

ISBN/ISSN
9798822547421 MWT15263248, 882254742X 15263248
LANGUAGE
English
NOTES

Please note: This is a companion version & not the original book. Book Preview: #1 Mike Babich was a wealth manager at Northern Trust, a Chicago banking institution, who was offered a job by a high-net-worth individual in the pharmaceutical business. He didn't know much about his client, but he accepted the offer. #2 Kapoor was a pharmaceutical industry mogul who made his fortune by developing generic medications. He was the largest shareholder in at least five companies. He had made a fortune as a biotech entrepreneur. #3 Kapoor's company, Lypho-Med, was a powerhouse in the generic drug business. In the 1980s, government incentives favored cheaper alternatives to branded medications. Kapoor was a consistent winner, and his company grew rapidly under his ownership. #4 After the acquisition, Lyphomed's value and reputation were destroyed. In 1992, Fujisawa sued Kapoor, alleging that he had concealed devastating FDA problems during the sale. The buyer was accusing Kapoor of selling a lemon

Mode of access: World Wide Web

Additional Credits